Logo image of AMPH

AMPHASTAR PHARMACEUTICALS IN (AMPH) Stock Price, Quote, News and Overview

NASDAQ:AMPH - Nasdaq - US03209R1032 - Common Stock - Currency: USD

24.68  +0.12 (+0.49%)

After market: 24.68 0 (0%)

AMPH Quote, Performance and Key Statistics

AMPHASTAR PHARMACEUTICALS IN

NASDAQ:AMPH (6/23/2025, 8:00:00 PM)

After market: 24.68 0 (0%)

24.68

+0.12 (+0.49%)

Sector
GICS SectorHealth Care
GICS IndustryPharmaceuticals
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryPharmaceuticals
Statistics
52 Week High53.96
52 Week Low22.64
Market Cap1.16B
Shares47.14M
Float36.21M
Yearly DividendN/A
Dividend YieldN/A
PE6.93
Fwd PE6.77
Earnings (Next)08-05 2025-08-05/amc
IPO06-25 2014-06-25


AMPH short term performance overview.The bars show the price performance of AMPH in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 -10 -20 -30

AMPH long term performance overview.The bars show the price performance of AMPH in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30 -40 -50

The current stock price of AMPH is 24.68 USD. In the past month the price increased by 1.98%. In the past year, price decreased by -38.3%.

AMPHASTAR PHARMACEUTICALS IN / AMPH Daily stock chart

AMPH Competitors/Peers

The largest stocks on the US markets in the "Pharmaceuticals" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
LLY ELI LILLY & CO 56.01 730.37B
JNJ JOHNSON & JOHNSON 15.06 364.09B
NVO NOVO-NORDISK A/S-SPONS ADR 19.21 309.79B
NVS NOVARTIS AG-SPONSORED ADR 14.14 232.11B
AZN ASTRAZENECA PLC-SPONS ADR 16.05 219.01B
MRK MERCK & CO. INC. 10.29 201.28B
PFE PFIZER INC 7.49 136.62B
SNY SANOFI-ADR 10.73 117.25B
BMY BRISTOL-MYERS SQUIBB CO 6.39 95.49B
GSK GSK PLC-SPON ADR 8.62 77.54B
ZTS ZOETIS INC 26.14 70.05B
HLN HALEON PLC-ADR 21.41 47.20B

About AMPH

Company Profile

AMPH logo image Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. The company is headquartered in Rancho Cucamonga, California and currently employs 2,028 full-time employees. The company went IPO on 2014-06-25. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers. The firm manufactures and sells over 25 products, such as BAQSIMI (glucagon) nasal powder 3mg, Primatene MIST, Glucagon for Injection Emergency Kit, Enoxaparin, Naloxone and Other Marketed Products, including Cortrosyn (cosyntropin for injection), Amphadase, Epinephrine injection, Lidocaine jelly, Lidocaine topical solution, Phytonadione injection, and others. The firm manufactures and sells two API products, Recombinant Human Insulin (RHI API) and porcine insulin API, for the injectable insulin market.

Company Info

AMPHASTAR PHARMACEUTICALS IN

11570 6th St

Rancho Cucamonga CALIFORNIA 91730 US

CEO: Jack Y. Zhang

Employees: 2028

AMPH Company Website

AMPH Investor Relations

Phone: 19099809484

AMPHASTAR PHARMACEUTICALS IN / AMPH FAQ

What is the stock price of AMPHASTAR PHARMACEUTICALS IN today?

The current stock price of AMPH is 24.68 USD. The price increased by 0.49% in the last trading session.


What is the ticker symbol for AMPHASTAR PHARMACEUTICALS IN stock?

The exchange symbol of AMPHASTAR PHARMACEUTICALS IN is AMPH and it is listed on the Nasdaq exchange.


On which exchange is AMPH stock listed?

AMPH stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for AMPHASTAR PHARMACEUTICALS IN stock?

12 analysts have analysed AMPH and the average price target is 33.66 USD. This implies a price increase of 36.39% is expected in the next year compared to the current price of 24.68. Check the AMPHASTAR PHARMACEUTICALS IN stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is AMPHASTAR PHARMACEUTICALS IN worth?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a market capitalization of 1.16B USD. This makes AMPH a Small Cap stock.


How many employees does AMPHASTAR PHARMACEUTICALS IN have?

AMPHASTAR PHARMACEUTICALS IN (AMPH) currently has 2028 employees.


What are the support and resistance levels for AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?

AMPHASTAR PHARMACEUTICALS IN (AMPH) has a support level at 23.35 and a resistance level at 25.47. Check the full technical report for a detailed analysis of AMPH support and resistance levels.


Is AMPHASTAR PHARMACEUTICALS IN (AMPH) expected to grow?

The Revenue of AMPHASTAR PHARMACEUTICALS IN (AMPH) is expected to decline by -1.48% in the next year. Check the estimates tab for more information on the AMPH EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does AMPHASTAR PHARMACEUTICALS IN (AMPH) stock pay dividends?

AMPH does not pay a dividend.


When does AMPHASTAR PHARMACEUTICALS IN (AMPH) report earnings?

AMPHASTAR PHARMACEUTICALS IN (AMPH) will report earnings on 2025-08-05, after the market close.


What is the Price/Earnings (PE) ratio of AMPHASTAR PHARMACEUTICALS IN (AMPH)?

The PE ratio for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 6.93. This is based on the reported non-GAAP earnings per share of 3.56 and the current share price of 24.68 USD. Check the full fundamental report for a full analysis of the valuation metrics for AMPH.


What is the Short Interest ratio of AMPHASTAR PHARMACEUTICALS IN (AMPH) stock?

The outstanding short interest for AMPHASTAR PHARMACEUTICALS IN (AMPH) is 11.31% of its float. Check the ownership tab for more information on the AMPH short interest.


AMPH Technical Analysis

ChartMill assigns a technical rating of 1 / 10 to AMPH. When comparing the yearly performance of all stocks, AMPH is a bad performer in the overall market: 89.25% of all stocks are doing better.


Chartmill TA Rating
Chartmill Setup Rating

AMPH Fundamental Analysis

ChartMill assigns a fundamental rating of 6 / 10 to AMPH. AMPH scores excellent on profitability, but there are some minor concerns on its financial health.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

AMPH Financial Highlights

Over the last trailing twelve months AMPH reported a non-GAAP Earnings per Share(EPS) of 3.56. The EPS decreased by -4.3% compared to the year before.


Industry RankSector Rank
PM (TTM) 19.38%
ROA 8.71%
ROE 18.85%
Debt/Equity 0.8
Chartmill High Growth Momentum
EPS Q2Q%-28.85%
Sales Q2Q%-0.76%
EPS 1Y (TTM)-4.3%
Revenue 1Y (TTM)8.05%

AMPH Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 77% to AMPH. The Buy consensus is the average rating of analysts ratings from 12 analysts.

For the next year, analysts expect an EPS growth of -16.92% and a revenue growth -1.48% for AMPH


Ownership
Inst Owners72.67%
Ins Owners8.72%
Short Float %11.31%
Short Ratio7.16
Analysts
Analysts76.67
Price Target33.66 (36.39%)
EPS Next Y-16.92%
Revenue Next Year-1.48%